The effect of cyclophosphamide on MSV-H oncogenesis.
The effect of cyclophosphamide on MSV-H oncogensis and the immune response of young mice has been investigated. A single, sublethal dose (100 and 50 mg/kg of cyclophosphamide) in 8-day-old mice given 24 h before or after MSV-H infection led to an earlier and lower incidence of tumours in comparison with controls infected only with MSV-H. The protective effect of cyclophosphamide, and the mechanism of action of both cyclophosphamide and MSV-H on the target cells, mesenchymal cells in rapid replication, as well the immunological implications of the findings are discussed.
D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D007109:Immunity / Q000187:drug effects*; D008198:Lymph Nodes / Q000276:immunology; D008231:Lymphopenia / Q000209:etiology; D051379:Mice; D009053:Sarcoma Viruses, Murine; D012513:Sarcoma, Experimental / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D013950:Thymus Gland / Q000473:pathology; D014412:Tumor Virus Infections / Q000276:immunology
D003520:Cyclophosphamide